Sign inJoin waitlistJoin the waitlist

Aparna Kamat

Physician · Houston Methodist Hospital

Credentials: · · · ·

History

Houston Methodist Hospital
2026–Present

Gynecologic Oncology
University of Texas M D Anderson Cancer Center
2005–2008
Obstetrics and Gynecology
West Virginia University School of Medicine
1997–2001
SETH G S MEDICAL COLLEGE, UNIV BOMBAY (MUMBAI), PAREL, MUMBAI, INDIA
1990–1994

Research

Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Nature Medicine · 2006 · 1,063 citations
Dicer, Drosha, and outcomes in patients with ovarian cancer
New England Journal of Medicine · 2008 · 564 citations
Stress hormone-mediated invasion of ovarian cancer cells
Clinical Cancer Research · 2006 · 408 citations

Anil Sood
39 papers
LH
Liz Han
30 papers · 29 as a resident
YL
Yvonne Lin-Liu
26 papers · 26 as a fellow
WM
William Merritt
25 papers · 25 as a resident
Charles Landen
22 papers · 20 as a fellow
David Gershenson
22 papers
RC
Robert Coleman
20 papers
Whitney Graybill
16 papers · 16 as a resident
CL
ChunHua Lu
13 papers
AN
Alpa Nick
9 papers · 9 as a fellow
GL
Gabriel Lopez-Berestein
8 papers
Premal Thaker
7 papers · 7 as a fellow

Clinical trials

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
Principal investigator · Not yet recruiting · Phase 2
The Methodist Hospital Research Institute
2027–2031
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Site PI · Recruiting · Phase 3
Verastem, Inc.
2024–2031
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012